Skip to content
Screener

Myriad Genetics MYGN Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$213.1MBeat by $7.9M
EPS$0.05Beat by $0.06
Revenue estimate$205.2M
EPS estimate-$0.01

Next report

Nov 2, 2026 (in a month)
Revenue estimate$191.4M
EPS estimate-$0.16

Financials

Q2 2025

Income statement

See full
Revenue$213.1M+0.8%
Gross profit$151.8M+3.2%
Operating income-$329.2M-802%
Net income-$330.5M-801%
EPS (diluted)-$3.57-771%

Balance sheet

See full
Cash & equivalents$83.7M-17.3%
Total debt$154.6M+7.9%
Total equity$388.1M-47.6%
Total assets$677.3M-37.6%

Cash flow

See full
Operating cash flow-$13.6M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$465.5M-76.7%
Enterprise value$536.4M-73.7%
P/S0.6×-1.9×

Profitability

See full
Gross margin70.4%+1.4pp
Operating margin-50.1%-137pp
Net margin-47.4%-152pp

Returns & leverage

See full
Return on equity-70%-123pp
Debt / equity0.4×+0.2×
Current ratio1.4×-0.5×

FAQ

When did Myriad Genetics report Q2 2025 earnings?
Myriad Genetics (MYGN) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Myriad Genetics's Q2 2025 revenue and EPS?
Myriad Genetics reported revenue of $213.1M and eps of $0.05 for Q2 2025.
Did Myriad Genetics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $205.2M by $7.9M. EPS beat the consensus estimate of $-0.01 by $0.06.
How did Myriad Genetics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.8% from $211.5M a year earlier and eps grew 0.0% from $0.05.
Where can I find Myriad Genetics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000899923-25-000084) and the 10-Q periodic report (0000899923-25-000086) directly on SEC EDGAR. The filing index links above go to sec.gov.